Inicio>>Signaling Pathways>> Metabolism>> PDE>>ATX inhibitor 5

ATX inhibitor 5

Catalog No.GC62403

El inhibidor de ATX 5 es un inhibidor de autotaxina (ATX) potente y activo por vÍa oral, con una IC50 de 15,3 nM.

Products are for research use only. Not for human use. We do not sell to patients.

ATX inhibitor 5 Chemical Structure

Cas No.: 2402772-45-4

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
329,00 $
Disponible
5 mg
315,00 $
Disponible
10 mg
522,00 $
Disponible
25 mg
990,00 $
Disponible
50 mg
1.530,00 $
Disponible
100 mg
2.250,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently[1].

ATX inhibitor 5 (compound 10g) (IC50s=1.21 and 0.78 μM) displays activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC)[1].ATX inhibitor 5 at 10 μM successfully suppresses collagen content induced by TGF-β[1].

ATX inhibitor 5 (20-40 mg/kg; p.o.; once daily for two weeks) reduces CCl4-induced hepatic fibrosis level prominently[1].

[1]. Jiang N, et al.Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis.Eur J Med Chem. 2020 Feb 1;187:111904.

Reseñas

Review for ATX inhibitor 5

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ATX inhibitor 5

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.